Venture Capital Industry News

A collection of Venture Capital latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

newswire.ca - Radical Ventures announces the largest venture capital fund in Canadian history
Radical Ventures announces the largest venture capital fund in Canadian history
CNW

With a focus on investing and partnering with AI companies scaling into global champions, well over US$1 billion has been committed to the strategy by PSP Investments, CPP Investments, HOOPP, TD Bank Group, BMO Financial Group, CI Global Asset…

thestandard.com.hk - The Standard 英文虎報 - China's DeepSeek hires dealmaker as CFO ahead of possible IPO
China's DeepSeek hires dealmaker as CFO ahead of possible IPO
The Standard

DeepSeek plans to hire Yan Wentao, a partner at venture-capital firm GL Ventures, as its first chief financial officer, two people with knowledge of the matter said, as the Chinese AI startup prepares for a potential initial public offering. SCROLL…

forbes.com - Lisa Zeiderman - Prenups For Founders And Early Employees With Venture-Backed Equity
Prenups For Founders And Early Employees With Venture-Backed Equity
Forbes

Lisa Zeiderman, Esq., CDFA, CFL, a Managing Partner at Miller Zeiderman, LLP, is a matrimonial and family law attorney based in New York. An early employee or founder of a venture capital-backed startup tends to have a financial picture that…

fortune.com - Allie Garfinkle - Sam Altman says OpenAI's IPO window has been pushed to 2027-but markets aren't the culprit
Sam Altman says OpenAI's IPO window has been pushed to 2027-but markets aren't the culprit
Fortune

OpenAI's still looking at an IPO—but not in 2026. On Friday, OpenAI CEO Sam Altman told Fortune editor-in-chief Alyson Shontell that it wasn't the right time. “I actually think that, given everything happening with safety, right now…

thestandard.com.hk - The Standard 英文虎報 - Doomers and boosters: who's who in the AI wars
Doomers and boosters: who's who in the AI wars
The Standard

The furious debate over artificial intelligence has hardened into warring camps -- and a cautious middle. SCROLL TO CONTINUE WITH CONTENT Here is a look at the battle lines in the war over a technology that is now the backbone of the economy and…

businessinsider.com - Amanda Chu, Hilary Brueck and Andreas Macho - The biotech industry wrote Montana's right-to-try law. Now they're running the show.
The biotech industry wrote Montana's right-to-try law. Now they're running the show.
Business Insider

Investors on the libertarian fringe of the biotech industry are making their dream of wide-ranging access to experimental drugs a reality in Montana. Last year, they helped draft a state law to expand access to drugs that no regulator has deemed…

wwd.com - Arthur Zaczkiewicz - Tech Tuesday: Unlocking Insights From Data
Tech Tuesday: Unlocking Insights From Data
WWD

This week, we hear from TrusTrace about a new compliance solution that turns complex supply chain data into actionable insights for brands. In other news, M11 Labs is making it easier to verify product claims—a sticky point when AI agents do…

digitaljournal.com - AFP - Doomers and boosters: who's who in the AI wars
Doomers and boosters: who's who in the AI wars
Digital Journal

The furious debate over artificial intelligence has hardened into warring camps — and a cautious middle. Here is a look at the battle lines in the war over a technology that is now the backbone of the economy and could decide the future of…

afr.com - Emma Rapaport, Zoe Samios - Airtree 'leaning in harder, earlier' after missed Eucalyptus payday
Airtree 'leaning in harder, earlier' after missed Eucalyptus payday
Australian Financial Review

In venture capital, landing the best investments early is just as important as avoiding the blow-ups. That's because the industry is built on the idea that most investments will go to zero, but a handful will deliver outsized returns. One of the…

iclg.com - Verity Jackson - K&L Gates raids Pillsbury for six new partners
K&L Gates raids Pillsbury for six new partners
ICLG

The latest cohort will bolster the firm's corporate, transactions, capital markets, intellectual property and litigation offering to clients. Global law firm K&L Gates has appointed six partners across its corporate, intellectual property…

thenyledger.com - Press Room - Greg Brockman says OpenAI has already slowed cutting-edge AI developments over safety concerns
Greg Brockman says OpenAI has already slowed cutting-edge AI developments over safety concerns
The New York Ledger

As the tech world continues debating whether to slow down AI development, OpenAI's cofounder said the company is already doing so. In multiple interview sessions aired on Monday, OpenAI cofounder and president Greg Brockman said that the company…

prnewswire.com - Euclyd - EUCLYD Raises Over €200 Million to Break the AI Efficiency Wall
EUCLYD Raises Over €200 Million to Break the AI Efficiency Wall
Cision PR Newswire

As foundation models grow more capable, deploying them requires more power, memory bandwidth, and capital while adding infrastructure complexity. EUCLYD is developing a platform spanning crafted compute, innovative memory architecture, and…

gizmodo.com - Bruce Gil - Barack Obama: 'I'm Not a Doomer
Barack Obama: 'I'm Not a Doomer
Gizmodo | The Future Is Here

Days after researchers at leading AI labs warned that the unchecked development of increasingly powerful AI could pose an existential risk, former President Barack Obama is weighing in. In a statement posted Monday on X, Obama wrote that he was…

jpost.com - ZELI GREENBERG - Israeli AI startup Buildots completes $130m. funding round
Israeli AI startup Buildots completes $130m. funding round
The Jerusalem Post

Israeli AI startup Buildots announced on Monday that it has completed a $130 million funding round, as the real estate AI and computer vision company sets its sights on an international market projected to reach approximately $1.4 trillion. The…

globenewswire.com - One04 Therapeutics - One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMD
One04 Therapeutics launches on encouraging CPV-104 Phase 1 interim results and plans to expand clinical development to include kidney diseases and dry AMD
GlobeNewswire

CPV-104 interim Phase 1 results support favorable safety and tolerability, with encouraging early efficacy trends in patients with C3 glomerulopathy Detailed interim Phase 1 data to be released in a virtual event after ASN Kidney Week One04 is…

Receive a Daily briefing on Venture Capital Industry News

Get Started